CAR-macrophage therapy alleviates myocardial ischemia-reperfusion injury
Male C57BL/6J mice, aged between eight to ten weeks were intravenously administered CAR-Ms/BMDMs/PBS at 3 days after myocardial ischemia/reperfusion. Transcriptional profiling was conducted on the hearts of mice that were injected with CAR-Ms/BMDMs/PBS 14 days after myocardial ischemia/reperfusion, as well as on a sham group.